期刊
JOURNAL OF CLINICAL NEUROSCIENCE
卷 19, 期 1, 页码 95-98出版社
ELSEVIER SCI LTD
DOI: 10.1016/j.jocn.2011.04.032
关键词
SLC22A18; Expression; Glioma; Immunohistochemical analysis; Prognosis
资金
- Natural Science Foundation of China [30901535]
- Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine [10XHJT01]
- Shanghai Jiao Tong University of School of Medicine [10XBR01]
We investigated the expression of the putative tumor suppressor SLC22A18 to evaluate it as a prognostic marker in glioma patients. Immunohistochemical and Western blot analyses of clinical tissue samples obtained from 120 patients with glioma were performed. Low expression of SLC22A18 was observed in 71.7% of patients. Loss of SLC22A18 expression in glioma was significantly related to pathological grade (p = 0.003). High pathological grade (World Health Organization III-IV) was correlated with negative (low or absent) expression of SLC22A18, which was correlated with a significantly shorter overall patient survival than in those with positive (high) expression (p = 0.007). Multivariate Cox regression analysis indicated that SLC22A18 expression level is an independent survival prognostic factor for patients with glioma (p = 0.011). Western blotting analysis confirmed decreased expression of SLC22A18 in glioma tissues compared with adjacent brain tissues. This study suggests that SLC22A18 functions as a tumor suppressor in glioma and represents a candidate biomarker for long-term survival in this disease. Crown Copyright (C) 2011 Published by Elsevier Ltd. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据